首页> 外文OA文献 >Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer
【2h】

Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer

机译:使用HER2靶向肽 - 脂质衍生物的配体肽接枝的聚乙二醇化脂质体在乳腺癌细胞中靶向递送:丝氨酸 - 甘氨酸重复肽作为间隔物的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ligand peptide-grafted PEGylated liposomes have been widely studied for targeted drug delivery systems. Because ligand peptides are commonly grafted using PEG as a spacer on the surface of PEGylated liposomes, the interaction between ligand peptides and their corresponding receptors can be interrupted by steric hindrance of the PEG layer. Therefore, we aimed to develop ligand peptide-lipid derivatives to enhance the targeting efficiency of ligand peptide-grafted PEGylated liposomes, and designed a new ligand peptide-lipid derivatives having serine-glycine repeats (SG)n as a spacer based on the peptide length calculated by PyMol (v0.99). We selected KCCYSL (KCC) as the ligand peptide for binding to human epidermal growth factor receptor-2 (HER2). We synthesized new KCC-(SG)n-lipid derivatives (n = 3, 5, 7) and evaluated their cellular association in breast cancer cells. KCC-(SG)n/PEGylated liposomes dramatically increased cellular association on HER2-positive breast cancer cells. The results suggest that KCC can be grafted on the surface of KCC-(SG)n/PEGylated liposomes prepared from KCC-(SG)n-lipid derivatives (n = 3, 5, 7). In summary, we succeeded in developing KCC-(SG)n-lipid derivatives for the preparation of ligand peptide-grafted PEGylated liposomes.
机译:配体肽接枝的聚乙二醇化脂质体已被广泛研究用于靶向药物递送系统。因为配体肽通常使用PEG作为间隔物接枝在PEG化脂质体的表面上,所以配体肽及其相应受体之间的相互作用可被PEG层的空间位阻所中断。因此,我们旨在开发配体肽-脂质衍生物以提高配体肽接枝的聚乙二醇化脂质体的靶向效率,并设计了一种新的以丝氨酸-甘氨酸重复序列(SG)n为间隔基的配体肽-脂质衍生物。由PyMol(v0.99)计算。我们选择KCCYSL(KCC)作为与人表皮生长因子受体2(HER2)结合的配体肽。我们合成了新的KCC-(SG)n-脂质衍生物(n = 3、5、7),并评估了它们在乳腺癌细胞中的细胞缔合。 KCC-(SG)n / PEG化脂质体显着增加了HER2阳性乳腺癌细胞上的细胞缔合。结果表明,可以将KCC移植到由KCC-(SG)n-脂质衍生物制备的KCC-(SG)n / PEG化脂质体的表面上(n = 3、5、7)。总之,我们成功地开发了用于配体肽接枝的PEG化脂质体的KCC-(SG)n-脂质衍生物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号